Divisions

Divisions

Stason entered the US generic market in 1994, and currently holds a portfolio of approved ANDAs. We are vertically integrated, from process development of the API to the submission of dossiers for finished products. This provides control over the supply chain and the ability to offer quality products at the right time and at competitive prices.

Stason offers a portfolio of generic pharmaceutical products that are marketed though our global distributors. These generic products are initially filed under an Abbreviated New Drug Application (ANDA). Future development in this area will focus on those generics that require high containment manufacturing, cytotoxic products and products that are difficult to manufacture. We believe these qualities present an increased barrier to market entry of our competitors.

Stasons core generic therapeutic categories include oncology, CNS, cardiovascular and dermatologic indications. Expanding our generic product portfolio, Stason is geared to file 4-5 or more ANDA’s per year in the areas of oncology and CNS.